Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Market Intel: Medtech Giants Ready To Battle Frontrunner Intuitive Surgical In 'Soft Surgery Robotics'
The global market for robotic surgery systems is expected to reach $9.7bn by 2023. With medtech giants Medtronic, Johnson & Johnson and Zimmer Biomet launching robotic platforms in 2020, this market is set for a major shakeup.
Latest From Market Intelligence
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about the most popular Market Intel stories in 2019 and next-generation insulin pumps expected to be introduced in 2020.
The Top 5 Market Intel Stories Of 2019: A Mixed Bag Of Hemodialysis, Robotics, Ophthalmology, Femtech And Liquid Biopsy
A look back at Medtech Insight’s five most-read Market Intelligence features of 2019 reveals a diverse mix of interests among our readers – hemodialysis, robotic surgeries, ophthalmic surgical solutions, liquid biopsy and digital technologies that seek to improve women's health.
Market Brief: Robotic Surgery Systems Market Will Reach $9.7Bn By 2023; Driven By Innovation, Procedure Volume Growth And Access To Emerging Markets
The global market for robotic surgery systems is expected to grow at a CAGR of 16%, reaching $9.7bn by 2023, driven by continued innovation, access to emerging markets and rising demand.
Market Brief: Abbott, Dexcom Help Drive Continuous Glucose Monitoring Market; 30% Expected Growth by 2023
Global sales of blood glucose monitoring devices are expected to reach $13bn by 2023, a CAGR of nearly 11%, led by the rising adoption of continuous glucose monitoring systems (CGMs). Abbott and Dexcom have been major drivers in the CGM market, but competition is fierce.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.